A pharmacist-managed clinic for treatment of latent tuberculosis infection in health care workers

American Journal of Health-System Pharmacy

Volumn 60, Issue 18, 2003, Pages 1856-1861

  Tavitian, Sandra M ^a   Spalek, Viola H ^a   Bailey, Raymond P ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Cedars Sinai Medical Center ^*

Author keywords

Ambulatory care; Antituberculars; Compliance; Health professions; Patients; Pharmacists; Toxicity; Tuberculosis

Indexed keywords

ISONIAZID; TUBERCULOSTATIC AGENT;

ARTICLE; FOLLOW UP; HEALTH CARE PERSONNEL; HEALTH CENTER; HUMAN; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PHARMACIST; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 10044266277     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.18.1856     Document Type: Article

References (15)

1. Tuberculosis morbidity among U.S.-born and foreign-born population - U.S., 2000. MMWR. 2002; 51:101-4.
2. Camins B, Bock N, Watkins D et al. Acceptance of isoniazid preventive therapy by health care workers after tuberculin skin test conversion. JAMA. 1996; 275:1013-5.
3. Menzies D, Tannenbaum TN, Fitzgerald JM. Tuberculosis: 10. Prevention. CMAJ. 1999; 161:717-24.
4. Ca. Code Reg. tide 22 (1996).
5. Clark NM. Patient compliance. Am Rev Respir Dis. 1992; 146:1376-7.
6. Marinker MA. From compliance to concordance: achieving shared goals in medicine taking. BMJ. 1997; 314:717-8.
7. American Thoracic Society and Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000; 161(suppl):S221-47.
8. Stuart RL, Grayson ML. A review of isoniazid-related hepatotoxicity during chemoprophylaxis. Aust N Z J Med. 1999; 29:362-7.
9. Update: total and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations - U.S., 2001. MMWR. 2001; 50:733-5.
10. Snider D, Hutton MD. Improving patient compliance in tuberculosis treatment programs. Atlanta: Centers for Disease Control; 1982.
11. Yew WW. Therapeutic drug monitoring in antituberculosis chemotherapy. Ther Drug Monit. 1998; 20:469-72.
12. Coleman LT, Adams WC, Gong WC. Pharmacist as a primary-care provider in a TB clinic. Am J Hosp Pharm. 1983; 40:278-81.
13. Dayton CS. Pharmacist involvement in a TB outpatient clinic. Am J Hosp Pharm. 1978; 35:708-10.
14. Chaisson RE, Barnes GL, Hackman J et al. A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. Am J Med. 2001; 110:610-5.
15. Tavitian SM, Kidder PA, Shane R. Contacting patients with unclaimed prescriptions: the pharmacist's impact on drug therapy concordance. Hosp Pharm. 2001; 36:1060-5.